EBA
CHRS icon

Eagle Bay Advisors’s Coherus Oncology CHRS Stock Holding History

Eagle Bay Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30
Closed -$72 – 993
2024
Q1 		$72 Sell
30
-39
-57% -$96 ﹤0.01% 967
2023
Q4 		$230 Sell
69
-5,164
-99% -$13.8K ﹤0.01% 817
2023
Q3 		$19.6K Buy
5,233
+3,729
+248% +$17.2K 0.01% 524
2023
Q2 		$6.42K Sell
1,504
-2,732
-64% -$16.1K ﹤0.01% 640
2023
Q1 		$29K Buy
4,236
+3,009
+245% +$23.4K 0.02% 486
2022
Q4 		$9.72K Sell
1,227
-2,775
-69% -$21.4K 0.01% 609
2022
Q3 		$39K Buy
4,002
+111
+3% +$1.12K 0.02% 393
2022
Q2 		$28.2K Buy
3,891
+2,243
+136% +$19.5K 0.02% 495
2022
Q1 		$21K Sell
1,648
-472
-22% -$6K 0.02% 227
2021
Q4 		$34K Buy
2,120
+354
+20% +$6.19K 0.02% 463
2021
Q3 		$28K Sell
1,766
-155
-8% -$2.27K 0.02% 532
2021
Q2 		$28K Buy
+1,921
New +$27.2K 0.02% 472

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Bay Advisors's CHRS Position: Q2 2024 in Review

Eagle Bay Advisors sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 30 shares — an estimated $72 sold.

Eagle Bay Advisors first reported a position in CHRS in Q2 2021 and held it in 12 quarters. The position peaked at $39K in Q3 2022. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • Eagle Bay Advisors reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • Eagle Bay Advisors sold 30 Coherus Oncology shares in Q2 2024, an estimated $72.
  • Eagle Bay Advisors first reported a position in Coherus Oncology in Q2 2021 and held it in 12 quarters.
  • Eagle Bay Advisors's Coherus Oncology position peaked at $39K in Q3 2022.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Eagle Bay Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.